The Multi Cancer Early Detection Market Size is valued at 1.20 Billion in 2024 and is predicted to reach 5.60 Billion by the year 2034 at a 16.8% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Multi-cancer early detection is a novel technique for spotting cancer in its early stages. Multi Cancer Early Detection is a novel technique for spotting cancer in its early stages. The test searches for certain antigens released into cancer patients' blood. There are numerous distinct cancer kinds, and each type has its collection of indicators. The Multi Cancer Early Detection test scans the blood of cancer patients for a particular set of markers. The market for multi-cancer early detection (MCED) is anticipated to grow due to factors including the rising incidence of cancer and the increased government emphasis on the early detection of cancers.
The market presents a significant opportunity, given a growing understanding that early cancer detection can improve patient survival and lower treatment costs. The development of MCED is undergoing extensive Research & Development to improve diagnostic performance. Additionally, the creation of tests that can precisely and continuously look for indications of a wide range of malignancies, the majority of which lack an effective screening method, is anticipated to fuel the expansion of the entire market.
Along with these other aspects, firms functioning in the global Multi Cancer Early Detection Market can anticipate profitable revenue growth potential due to rising R&D activities, government initiatives to employ sustainable components in production and investments from well-known companies.
The multi cancer early detection market is segmented based on product and end user. Based on type, the market is segmented as liquid biopsy and gene panel, LDT and Others. By end user, the market is segmented into hospitals, diagnostic laboratories and other.
The liquid biopsy category is expected to hold a major share in the global multi-cancer early detection market in 2021. Cancer detection's great uptake and acceptance are credited with the segment's supremacy. One of the innovative and newest advances in diagnostics is a liquid biopsy which is expected to drive the market further.
The hospital segment is projected to grow at a rapid rate in the global multi-cancer early detection market. Medical professionals with specialized training and other healthcare workers involved in diagnosis and treatment are responsible for this segment's dominance. Hospitals inform and raise public knowledge of various illnesses and ailments. The target audience knows very little about MCED, a new technology. As a result, hospitals examine asymptomatic people for several types to facilitate therapy, especially in countries such as the US, Germany, the UK, China, and India.
The North American multi-cancer early detection market. Some major components propelling market expansion in North America are the increasing cancer frequency, the accessibility of cutting-edge medical infrastructure, and the involvement of significant players here. In addition, Asia Pacific is accounted to hold the highest share in the global multi-cancer early detection market. One of the key reasons propelling market expansion in this region is the escalating disease population and the expanding government measures to improve early cancer detection.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.20 Billion |
|
Revenue Forecast In 2034 |
USD 5.60 Million |
|
Growth Rate CAGR |
CAGR of 16.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type, End-Use |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; Germany; China; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; Japan; India; South Korea; South East Asia |
|
Competitive Landscape |
Grail, LLC (Illumina, Inc.), Exact Sciences Corporation, Foundation Medicine, Inc., AnchorDx, Guardant Health, Inc., Burning Rock Biotech Limited, GENECAST, Laboratory for Advanced Medicine, Inc., and Singlera Genomics Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multi Cancer Early Detection Market Snapshot
Chapter 4. Global Multi Cancer Early Detection Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product Type:
5.2.1. Liquid Biopsy
5.2.2. Gene Panel, LDT and Others
Chapter 6. Market Segmentation 2: by End-users Estimates & Trend Analysis
6.1. by End-users & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-users:
6.2.1. Hospitals
6.2.2. Diagnostic Laboratories
6.2.3. Others
Chapter 7. Multi Cancer Early Detection Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.1.2. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2021-2034
7.1.3. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2021-2034
7.2.2. Europe Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2021-2034
7.2.3. Europe Multi Cancer Early Detection Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2021-2034
7.3.2. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2021-2034
7.3.3. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2021-2034
7.4.2. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2021-2034
7.4.3. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2021-2034
7.5.2. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2021-2034
7.5.3. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 Micronoma Inc
8.2.2 Anpac Bio
8.2.3 EarlyDiagnostics, Inc
8.2.4 Early is Good (EIG)
8.2.5 Cansense
8.2.6 Freenome Holdings, Inc.
8.2.7. Oncocyte Corporation
8.2.8 SeekIn
8.2.9 Naveris
8.2.10 VESEN, Inc.
8.2.11 Grail, LLC (Illumina, Inc.)
8.2.12 Exact Sciences Corporation
8.2.13 Foundation Medicine, Inc.
8.2.14 AnchorDx
8.2.15 Guardant Health, Inc.
8.2.16 Burning Rock Biotech Limited
8.2.17 GENECAST
8.2.18 Laboratory for Advanced Medicine, Inc.
8.2.19 Singlera Genomics Inc.
By Type
By End Use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
